jetcityimage/iStock Editorial via Getty Images
Eli Lilly (NYSE:LLY) shares slipped ~12% in the premarket on Thursday after the company disclosed topline data from a late-stage trial for its oral GLP-1 receptor agonist orforglipron targeting obese or overweight adults.
Novo Nordisk (NVO), LLY’s main rival in the obesity drug market, added ~7% in reaction.
Citing its 72-week data, the Indiana-based pharma giant said its Phase 3 ATTAIN-1 trial hit the primary endpoint and all key secondary endpoints in the study, which enrolled more than 3,000 adults with obesity or overweight.
As for the main goal, once-daily orforglipron at 36 mg led to an average weight loss of 12.4% (27.3 lbs) compared to a 0.9% (2.2 lbs) average weight loss experienced by those on placebo, the company said, citing a per-protocol analysis.
Eli Lilly (NYSE:LLY) continues to plan regulatory submissions for orforglipron globally by the end of this year.